Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

Detailed price information for Xoma Royalty Corporation (XOMA-Q) from The Globe and Mail including charting and trades.

XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.

Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or ...

See the latest XOMA Royalty Corp stock price (XOMA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

XOMA Royalty Corp. Annual cash flow by MarketWatch. View XOMA net cash flow, operating cash flow, operating expenses and cash dividends.

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) were trading at $393.83, down $78.44, or 16%, on top-line results from the phase II dose-ranging study evaluating the safety and efficacy of its ...

View the latest XOMA Royalty Corp. 8.625% Pfd. Series A (XOMAP) stock price, news, historical charts, analyst ratings and financial information from WSJ.